Novel coronavirus disease 2019 (COVID-19) is known to cause severe pneumonia and acute respiratory distress syndrome which may lead to death. Several treatments have been tested in the race to find a treatment regimen for this deadly viral infection. Tocilizumab, a recombinant humanized anti-interleukin-6 receptor monoclonal antibody, has been used and found to be beneficial in patients with COVID-19 and in cytokine storm. We present the case of a young, otherwise healthy male, presenting with COVID-19 and successfully treated in the intensive care unit with tocilizumab.


中文翻译：

---

抗白细胞介素6单克隆抗体，用于COVID-19中的细胞因子风暴。


已知新型冠状病毒病2019（COVID-19）会导致严重的肺炎和急性呼吸窘迫综合症，甚至可能导致死亡。为了寻找这种致命病毒感染的治疗方案，已经在竞赛中测试了几种治疗方法。重组人源化抗白介素6受体单克隆抗体Tocilizumab已被使用，发现对COVID-19患者和细胞因子风暴有益。我们介绍了一个年轻的，否则为健康的男性的案例，该患者出现了COVID-19，并在重症监护病房成功接受了tocilizumab的治疗。